Yazar "Yuksel, H." seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • [ X ]
    Öğe
    Does atopy affect the course of viral pneumonia?
    (Elsevier Espana Slu, 2018) Erdem, S. B.; Can, D.; Girit, S.; Catal, F.; Sen, V.; Pekcan, S.; Yuksel, H.
    Background: The presence of atopy is considered as a risk factor for severe respiratory symptoms in children. The objective of this study was to examine the effect of atopy on the course of disease in children hospitalised with viral pneumonia. Methods: Children between the ages of 1 and 6 years hospitalised due to viral pneumonia between the years of 2013 and 2016 were included to this multicentre study. Patients were classified into two groups as mild-moderate and severe according to the course of pneumonia. Presence of atopy was evaluated with skin prick tests. Groups were compared to evaluate the risk factors associated with severe viral pneumonia. Results: A total of 280 patients from nine centres were included in the study. Of these patients, 163 (58.2%) were male. Respiratory syncytial virus (29.7%), Influenza A (20.5%), rhinovirus (18.9%), adenovirus (10%), human metapneumovirus (8%), parainfluenza (5.2%), coronavirus (6%), and bocavirus (1.6%) were isolated from respiratory samples. Eighty-five (30.4%) children had severe pneumonia. Atopic sensitisation was found in 21.4% of the patients. Ever wheezing (RR: 1.6, 95% CI: 1.1-2.4), parental asthma (RR: 1.5, 95% CI: 1.1-2.2), other allergic diseases in the family (RR: 1.8, 95% CI: 1.2-2.9) and environmental tobacco smoke (RR: 1.6, 95% CI: 1.1-3.5) were more common in the severe pneumonia group. Conclusions: When patients with mild-moderate pneumonia were compared to patients with severe pneumonia, frequency of atopy was not different between the two groups. However, parental asthma, ever wheezing and environmental tobacco smoke exposure are risk factors for severe viral pneumonia in children. (C) 2017 SEICAP. Published by Elsevier Espana, S.L.U. All rights reserved.
  • [ X ]
    Öğe
    Fibrosis in heart failure subtypes
    (Verduci Publisher, 2013) Toprak, G.; Yuksel, H.; Demirpence, O.; Islamoglu, Y.; Evliyaoglu, O.; Mete, N.
    BACKGROUND: The differences in concentrations of biomarkers between heart failure patients with dilated cardiomyopathy (HF-D) and with ischemic cardiomyopathy (HF-I) have yet to be defined. The objectives of this study were to compare the concentrations and correlation of biomarkers of inflammation, extracellular matrix (ECM) turnover and oxidative stress parameters between these populations. PATIENTS AND METHODS: Our study consisted of 36 subjects with HF-D (LVSD = 47.2 +/- 7.3 mm, LVDD = 65.1 +/- 6.3 mm), 44 subjects with HF-I (LVSD = 38.0 +/- 4.4 mm, LVDD = 58.5 +/- 6.0 mm) and 38 controls without heart failure. Concentrations of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, MMP-13, Galectin-3, prolidase, TNF-alpha, and oxidative stress index (OSI) were measured. RESULTS: Serum levels of MMP-2, MMP-9, and prolidase were significantly increased in HF-I group compared to healthy controls (p = 0.039, 0.019, 0.012 respectively), whereas the increases in MMP-1 and MMP-13 were not significant. This significance was stronger in the HF-D group than the HF-I group (p = 0.004, 0.001, 0.002 respectively). TNF-alpha, a marker of inflammation, was significantly increased in heart failure (p = 0.004) but there was no difference between HF-D and HF-I groups; however, Galectin-3 was significantly increased in the HF-D group compared to the HF-I group (p = 0.005). OSI showed the same response pattern as TNF-alpha (p = 0.019, 0.002 respectively). There was a positive correlation of MMP-9 levels with prolidase activity (r = 0.612, p: 0.003). CONCLUSIONS: MMPs and Galectin-3 are important in cardiac remodeling; prolidase may share an undefined role in fibrosis in heart failure and may have a role in the diffuse fibrosis of heart failure.
  • [ X ]
    Öğe
    The Protective Effect of Ellagic Acid on Lung Damage Caused by Experimental Obstructive Jaundice Model
    (Acta Medical Belgica, 2013) Gul, M.; Aliosmanoglu, I.; Uslukaya, O.; Firat, U.; Yuksel, H.; Gumus, M.; Ulger, B. V.
    Aim : This study aimed to investigate protective effects of ellagic acid on lungs in an experimental obstructive jaundice model. Methods : Four groups were established, each consisting of ten randomly selected rats : Group 1: sham, Group 2: ellagic acid, Group 3 : obstructive jaundice, and Group 4 : obstructive jaundice + ellagic acid. Ellagic acid was administered orally at a dose of 60 mg/kg/day to group 2 and 4. The animals were sacrificed eight days later. The total oxidative status and the total antioxidant capacity in their lung tissue were determined, and malondialdehyde levels in their blood were measured. Histopathological changes in the lungs were examined. Results : In the obstructive jaundice group treated with ellagic acid, there was a decrease in malondialdehyde levels and a reduction in the total oxidative status and the oxidative stress index, whereas the total antioxidant capacity increased (p < 0.001). The histopathological examination showed that neutrophil leukocyte infiltration and edema formation decreased and destruction of lung parenchyma disappeared following the treatment with the ellagic acid (p < 0.05). Conclusion : This study shows that ellagic acid has a protective effect against oxidative damage in lung tissue in obstructive jaundice.
  • [ X ]
    Öğe
    The protective effects of pomegranate on liver and remote organs caused by experimental obstructive jaundice model
    (Verduci Publisher, 2016) Yilmaz, E. E.; Arikanoglu, Z.; Turkoglu, A.; Kilic, E.; Yuksel, H.; Gumus, M.
    OBJECTIVE: We aimed to investigate the protective potential of pomegranate extract on the liver and remote organs in rats with obstructive jaundice. MATERIALS AND METHODS: The rats were split into 4 groups. In Group 1 (G1) (sham group) rats, the common bile duct was mobilized without any ligation. Group 2 (G2) received a combination of the sham operation and synchronous treatment with pomegranate. Group 3 (G3) received common bile duct ligation (CBDL). Group 4 (G4) were subjected to CBDL and treatment with pomegranate. After 8 days, we measured total oxidative status (TOS) and antioxidant capacity in the rats' liver tissue and remote organs, and evaluated blood levels of malondialdehyde and total antioxidant capacity (TAC). RESULTS: G3 rats showed significantly raised malondialdehyde level as compared to G1 rats (p < 0.001). Following the pomegranate therapy, a decrease in malondialdehyde was observed (p = 0.015). TAC levels were significantly raised in the G3 rats compared to the G1 rats (p = 0.004). TAC levels dropped after pomegranate therapy (p = 0.011). CBDL caused elevated TOS levels in the liver and remote organs, with a statistically significant increase in the lung tissue (p = 0.002). TOS levels in the CBDL groups decreased after pomegranate treatment (p < 0.001). CONCLUSIONS: This study reveals the marked protective effect of pomegranate on the liver and remote organs in obstructive jaundice.
  • [ X ]
    Öğe
    SERUM COENZYME-Q10 ACTIVITY AND OXIDATIVE STATUS IN PATIENTS WITH FIBROMYALGIA
    (Bmj Publishing Group, 2013) Bozkurt, M.; Oktayoglu, P.; Ucar, D.; Em, S.; Caglayan, M.; Yuksel, H.; Batmaz, I.
    [Abstract Not Available]
  • [ X ]
    Öğe
    Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity
    (Springer London Ltd, 2018) Sahin, A.; Gursel-Ozkurt, Z.; Sahin, M.; Turkcu, F. M.; Yildirim, A.; Yuksel, H.
    We aimed to investigate the effectivity of the 0.0625 mg dose of bevacizumab in patients with retinopathy of prematurity (ROP) and compare the results with 0.625 mg dose of intravitreal bevacizumab (IVB) injection. The medical records of the patients with type 1 ROP who received IVB monotherapy were retrospectively reviewed. Demographic and clinical characteristics of the patients were recorded. The patients were classified into two groups with respect to received dose of bevacizumab as follows: group F (n = 46) (full dose of bevacizumab-0.625 mg/0.025 ml) and group L (n = 45) (low dose (one tenth) of bevacizumab-0.0625 mg/0.025 ml). Both treatment dose regimens have similar outcomes. Moreover, the mean retinal vascularization time seemed to be significantly higher in group F compared to group L, 168 +/- 65 and 97 +/- 29 days, respectively (p < 0.001). Disappearance of plus sign is observed earlier in group F (2.45 +/- 1.7 vs 3.66 +/- 2.46 days, respectively, p = 0.03). The low dose (0.0625 mg) of IVB treatment was effective as full (0.625 mg) dose in ROP treatment. Moreover, our results showed that low-dose treatment might provide faster retinal vascularization than the regular used dose. On the other hand, disappearance of the plus sign takes longer time in patients treated with low dose compared to eyes treated with full dose of IVB that should be taken into account.